These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 5655479)

  • 21. [The influence of pharmaceutical and physico-chemical factors of drugs on the result of clinical trials: chloramphenicol palmitate].
    van Oudtshoorn MC; Potgieter FJ; Koeleman HA; Pantonowitz LD
    S Afr Med J; 1969 Nov; 43(45):1375-6. PubMed ID: 4902056
    [No Abstract]   [Full Text] [Related]  

  • 22. Proceedings: Bioavailability and therapeutic efficacy.
    Withey RJ
    Rev Can Biol; 1973; 32():Suppl:21-30. PubMed ID: 4777602
    [No Abstract]   [Full Text] [Related]  

  • 23. Absorption of chloramphenicol sodium succinate after intramuscular administration in children.
    Shann F; Linnemann V; Mackenzie A; Barker J; Gratten M; Crinis N
    N Engl J Med; 1985 Aug; 313(7):410-4. PubMed ID: 4022068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of rabbits for absorption studies on polymorphs of chloramphenicol palmitate.
    Maeda T; Takenaka H; Yamahira Y; Noguchi T
    Chem Pharm Bull (Tokyo); 1980 Feb; 28(2):431-6. PubMed ID: 7389018
    [No Abstract]   [Full Text] [Related]  

  • 25. [Kinetics of the absorption of D-chloramphenicol following its peroral and intramuscular administration].
    Nadvornikova G; Grafnetterova I; Shiuk O
    Antibiotiki; 1974 Dec; 19(12):1068-73. PubMed ID: 4447345
    [No Abstract]   [Full Text] [Related]  

  • 26. Chloromycetin palmitate; observations on absorption, blood serum levels, and urinary excretion.
    YOW EM; TAYLOR FM; HIRSCH J; FRANKEL RA; CARNES HE
    J Pediatr; 1953 Feb; 42(2):151-6. PubMed ID: 13023513
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of bioavailability of two chloramphenicol preparations in dogs after intramuscular injection.
    Bergt G; Stowe CM
    Am J Vet Res; 1975 Oct; 36(10):1481-2. PubMed ID: 1190590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical applications of polymorphism.
    Haleblian J; McCrone W
    J Pharm Sci; 1969 Aug; 58(8):911-29. PubMed ID: 4899118
    [No Abstract]   [Full Text] [Related]  

  • 29. [Problems in the rectal use of chloramphenicol].
    Briedigkeit W; Göres E; Schneeweiss B; Wachholz E; Wiegand U
    Padiatr Grenzgeb; 1972; 11(4):241-51. PubMed ID: 4662526
    [No Abstract]   [Full Text] [Related]  

  • 30. [Bioavailability of levomycetin preparations for oral use].
    Batuashvili TA; Zak AF
    Antibiotiki; 1983 Oct; 28(10):751-4. PubMed ID: 6651263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concentration of chloramphenicol in the urine and blood in relation to renal function.
    Lindberg AA; Nilsson LH; Bucht H; Kallings LO
    Br Med J; 1966 Sep; 2(5516):724-8. PubMed ID: 5917389
    [No Abstract]   [Full Text] [Related]  

  • 32. Chloramphenicol and the neonatal calf.
    Burrows GE; Tyler RD; Craigmill AL; Barto PB
    Am J Vet Res; 1984 Aug; 45(8):1586-91. PubMed ID: 6476571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rate studies on in vitro dissolution and in vivo absorption of chloramphenicol.
    Andersgaard H; Finholt P; Gjermundsen R; Hoyland T
    Acta Pharm Suec; 1971 Sep; 8(4):403-14. PubMed ID: 5135174
    [No Abstract]   [Full Text] [Related]  

  • 34. Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver.
    Azzollini F; Gazzaniga A; Lodola E; Natangelo R
    Int J Clin Pharmacol; 1972 Jun; 6(2):130-4. PubMed ID: 4638972
    [No Abstract]   [Full Text] [Related]  

  • 35. [Chloramphenicol in human bacteriological infections. Bacteriological and clinical observations].
    Saraceni G; Diana L; Lechi A; Sgoifo E; Fameli O
    Recenti Prog Med; 1968 Feb; 44(2):132-53. PubMed ID: 4909755
    [No Abstract]   [Full Text] [Related]  

  • 36. [On the relative measurement of the enteral resportion of drugs with the aid of pharmacokinetically determined serum level curves with the example of chloramphenicol].
    Betzien G; Vömel W
    Arzneimittelforschung; 1966 Aug; 16(8):1008-18. PubMed ID: 6014882
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of physical and pharmaceutical factors involved in drug release and availability from chloramphenicol capsules.
    Aguiar AJ; Wheeler LM; Fusari S; Zelmer JE
    J Pharm Sci; 1968 Nov; 57(11):1844-50. PubMed ID: 5725910
    [No Abstract]   [Full Text] [Related]  

  • 38. [Levomycetin dispersity and its effect on the intensity of absorption].
    Batuashvili TA
    Antibiotiki; 1980 Aug; 25(8):585-9. PubMed ID: 7406470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bioavailability of peroral antibiotic preparations].
    Zak AF
    Antibiotiki; 1977 Mar; 22(3):265-79. PubMed ID: 322606
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of hemodialysis on total body clearance of chloramphenicol.
    Slaughter RL; Cerra FB; Koup JR
    Am J Hosp Pharm; 1980 Aug; 37(8):1083-6. PubMed ID: 7405936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.